Poolbeg Pharma’s results highlight expansion potential and promising new assets

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

The year 2020 will be remembered for its tragic events, but in its wake, companies like Poolbeg Pharma are leading efforts to prepare for future pandemics. Richard Staines from Optimum Strategic Communications interviewed Jeremy Skillington, the

The pharmaceutical sector is continuously evolving, with several key patents set to expire in the coming years. To ensure the development of next-generation treatments, companies must stay abreast of the latest trends. Clarivate’s annual Drugs To

New research published in the journal Drug Discovery Today reveals that drugs discovered through artificial intelligence (AI) have a significantly higher success rate in Phase I clinical trials (80-90%) compared to those discovered by humans (40-65%).

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma announced significant advances and strategic expansions in its latest financial year, most notably with POLB 001 targeting a market opportunity exceeding $10 billion in cancer immunotherapy-induced Cytokine Release Syndrome (CRS). In its 2023 fiscal

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement

The culture of collaboration in the Pacific Northwest, the impact of AI on biopharma, and the shape of new business models driven by AI were all topics at a panel discussion Wednesday in Seattle at the

Poolbeg Pharma is very pleased to see the approval of multiple CAR T cell therapies for earlier treatment of multiple myeloma. As an oral preventative therapy for CRS, POLB 001 has the potential to enable broader,

On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer

Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application. This AIM-traded firm said the development pertained to POLB 001, a potent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant